EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte Studie

Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab

Joseph J Eron iD, Paul P Cook, Megha L Mehrotra iD, Hailin Huang, Marina Caskey iD, Gordon E Crofoot, Linda Gorgos, Laurie A VanderVeen, Yanan Zheng iD, Sean E Collins, Olayemi O Osiyemi, Cynthia Brinson und 1 weitere

The Journal of Infectious Diseases · 11.07.2025 · 231 (6) · 1440-1444

DOI: 10.1093/infdis/jiaf159 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 03.04.2025. Verfasst von Joseph J Eron und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Broadly Neutralizing Antibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Gilead Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of 2 broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only 1 of the 2 bNAbs.

Methods

This was a pilot study within a proof-of-concept phase 1b study.

Results

No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26.

Conclusions

More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV InfectionsHIV-1AdultFemaleHumansMaleMiddle AgedDrug Therapy, CombinationPilot ProjectsProof of Concept StudyAcetamidesIndazoles

Stichwörter der Autor:innen

HIVHIV-1HIV-1 therapyadherencebnAbslenacapavirlong actingsusceptibilityteropavimabzinlirvimab

Substanzen

Anti-HIV AgentsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBroadly Neutralizing AntibodieslenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Infectious Diseases, East Carolina University, Greenville, North Carolina, USA.
  • Cinical Research, Gilead Sciences, Inc, Foster City, California, USA.
  • Biostatistics, Gilead Sciences, Inc, Foster City, California, USA.
  • Laboratory of Molecular Immunology, Rockefeller University, New York, New York, USA.
  • Crofoot MD Clinic and Research Center, Houston, Texas, USA.

ORCID-Profile: Joseph J Eron, Megha L Mehrotra, Marina Caskey, Yanan Zheng

Förderung

  • Gilead Sciences, Inc

Zitieren

APA

Eron, J. J., Cook, P. P., Mehrotra, M. L., Huang, H., Caskey, M., Crofoot, G. E., Gorgos, L., VanderVeen, L. A., Zheng, Y., Collins, S. E., Osiyemi, O. O., Brinson, C., & DeJesus, E. (2025). Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of Infectious Diseases, 231(6), 1440-1444. https://doi.org/10.1093/infdis/jiaf159

Vancouver

Eron JJ, Cook PP, Mehrotra ML, Huang H, Caskey M, Crofoot GE, et al. Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of Infectious Diseases. 2025;231(6):1440-1444. doi:10.1093/infdis/jiaf159

BibTeX
@article{Eron2025,
  author = {Eron, Joseph J and Cook, Paul P and Mehrotra, Megha L and Huang, Hailin and Caskey, Marina and Crofoot, Gordon E and Gorgos, Linda and VanderVeen, Laurie A and Zheng, Yanan and Collins, Sean E and Osiyemi, Olayemi O and Brinson, Cynthia and DeJesus, Edwin},
  title = {Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {231},
  number = {6},
  pages = {1440--1444},
  doi = {10.1093/infdis/jiaf159}
}
Kostenlos starten →